Introduction
Atrial fibrillation (AF) is a frequent complication following coronary artery bypass graft (CABG) surgery (11-40%) [1] [2] , usually occurring on the second or third post-operative day. Different studies demonstrated that post-operative AF can lead to discomfort and hemodynamic instability with an increased hospital length stay [3] . Several drugs are used for prevention of post-operative AF, such as beta-blockers, ACE inhibitors and statins. However during the last few years the attention on n-3 polyunsaturated fatty acids (PUFA) has increased: previous studies demonstrated anti-arrhythmic properties reducing the risk of sudden cardiac death and ventricular arrhythmias [4] .
Other studies found that the human consumption of fish induced-high plasma PUFA concentration is was associated with a lower incidence of AF in a 12-year follow-up study [5] . A recent trial investigated the efficacy of pre-operative and post-operative treatment with PUFA in preventing the occurrence of AF after coronary artery bypass graft surgery; the investigators found that fish oil supplementation for at least 5 days until surgery and continued after surgery was able to reduce the incidence of postoperative AF resulting in a shorter hospital stay [6] . Other authors recently showed that preoperative PUFA therapy was associated with a decreased incidence of early, but not late, AF after cardiac surgery [7] .
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could have a role in reducing the production of proinflammatory cytokines [9] .
In the present study we hypothesized that preoperative and post-operative treatment with n-3 PUFA can prevent the occurrence of AF after CABG, taking into account the different surgical technique ("on-pump" or "off-pump" CABG).
Methods

Study population
From September 2009 to October 2010, 273 consecutive patients underwent CABG in our Institution. Among these, 72 were excluded. Exclusion criteria were: previous history of AF (12 pts) , previous anti-arrhythmic treatment (unless with betablockers, Ca-antagonists)(10 pts), severe valvular disease requiring surgery (32 pts), different technical strategy of the surgeon (18 pts). Inclusion criteria were: > 18 years, normal sinus rhythm and stable hemodynamic condition before cardiac surgery.
Two hundred and one consecutive eligible patients (164 men and 37 women; mean age 63 ± 10 years) undergoing CABG were enrolled in our study. All enrolled patients provided written informed consent to take part in the study.
Study design
These 201 eligible patients were assigned by randomization to a control group and to the PUFA (commercially available by Sigma Tau, Industrie Farmaceutiche Riunite, s.p.a. Italy) group. According to the surgical technique adopted, the groups were further divided into subgroups as follow: G1 group for PUFA patients operated with "off-pump" technique; G2 group for PUFA patients operated with "on-pump" technique; G3 group for patients operated with "off-pump" technique and not taking PUFA; G4 group for patients operated with "onpump" technique and not taking PUFA.
The choice of operating technique was randomized. The groups and the subgroups were selected according to homogeneity criteria.
This was a randomized prospective controlled study with parallel groups; the protocol was approved by the ethics committee of our institution.
Among the 201 patients enrolled, 96 were treated with PUFA-n3: they were administered with a daily dose of two gelatinous capsules containing 850 to 882 mg eicosapentaenoic acid and docosahexaenoic acid as ethyl esters in the average ratio of EPA/DHA 1:2 beginning five days before surgery and going on until discharge. The remaining 105 patients constituted the control group. The surgical access was obtained with a median sternotomy in all patients. Induction and anesthesia was the same in all patients. Myocardial protection was afforded with normotermic hematic potassium cardioplegia. Calculated heparin dosages were different in the two techniques (halved values in the off-pump patients). All anastomoses were sutured by hand.
Intensive care unit (ICU) standardized protocol implied 48 hours stay after surgery. Once discharged, patients were transferred to a monitored unit, where 3-lead telemetric monitoring was performed continuously for at least 4 days after the operation. In addition, patients had a 12-lead ECG daily until hospital discharge and an ECG was also performed in case of symptoms or when an arrhythmia was suspected. Patients who had AF were treated with intravenous injection of amiodarone and discharged with instructions to undergo oral amiodarone therapy for at least 30 days. Demographic and clinical pre-operative data are summarized in Table 1 .
Study endpoints
The primary end point of the study was to evaluate the incidence of post-operative in-hospital AF in the four groups. AF was defined as an episode of AF that lasted >5 minutes, or any episode requiring a treatment for hemodynamic compromise. After an episode of AF or at hospital discharge, formal study participation ended. Secondary end points were: 1) impact of surgical technique ("off-pump"/ "onpump") on the incidence of post-operative AF; 2) length of post-operative hospital stay.
Statistical analysis
The occurrence of post-operative AF in the two treatment groups was tested with the odds ratio (OR) of two-binomial proportion analysis. Mean (±SD) were calculated for continuous variables, and frequencies were measured for categorical variables. Differences between groups were analyzed by an unpaired Student T test for continuous variables, or chi-square tests in the case of categorical variables. A p value < 0.05 was considered significant.
Results
105 patients were assigned by randomization to the control group and 96 to the PUFA group. G1 group comprised 45 of 201 patients (22.4%); G2 group comprised 51 patients (25.4%); G3 group comprised 48 patients (23.9%); G4 group comprised 57 patients (28.3%) ( Table 2) .
Implanted grafts were left internal mammary artery (LIMA) in 200 pts, right internal mammary artery (RIMA) in 25 pts, radial artery (RA) in 33 pts and sapheneous vein (SVG) in 165 pts.
The overall incidence of post-operative AF was 17.4% (35 of 201 patients). Post-operative AF occurred in 11.4% of the patients (11 of 96 patients) in PUFA therapy (G1-G2) and in 22.8% (24 of 105) of the control groups (G3-G4)(OR 0.43; 95% CI 0.2-0.95; p = 0.033 by chi-square). In particular in the various subgroups the incidence of AF was: 11.1% in G1 (5 of 45), 11.7% in G2 (6 of 51), 12.5% in G3 (6 of 48) and of 31.6% in G4 (18 of 57). The statistical analysis showed a significant effect in favour of the PUFA group compared with controls only between G2 and G4 groups (OR 0.28; p = 0.013 by chi-square) (Figure 1 ). No differences were found between G1 and G3 groups (OR 0.87; p = 0.835 by chi-square).
No differences were found among groups regarding length of hospital stay (8±4 days, p = ns).
No patient developed allergic skin rash during PUFA therapy. Non fatal postoperative complications occurred in 10 patients (10.7%) in which "offpump" technique was adopted (G1 and G3 groups): four kidney failure, four implantation of intra-aortic pumping balloon, two respiratory failure; neigher in 12 patients (11.1%) in which "on-pump" technique was performed (G2 and G4 groups): three kidney failure, four implantation of intra-aortic pumping balloon, two respiratory failure, two mediastinitis, one surgical wound infection. Surgical re-exploration for bleeding was required in three patients operated with off-pump technique. There was no operative mortality. G1 = Off-pump CABG, treated with PUFA. G2 = On-pump CABG, treated with PUFA. G3 = Off-pump CABG without PUFA. G4 = On-pump CABG without PUFA. NYHA = New York Heart Association. COPD = chronic obstructive pulmonary. PUFA = polyunsaturated fatty acids. ACE = angiotensin-converting enzyme. LV = left ventricle. AP = antero-posterior. 
N-3 PUFA AND POST-OPERATIVE ATRIAL FIBRILLATION
Discussion
AF is the most common complication associated with CABG [1] [2] and can lead to discomfort and hemodynamic instability [3] . During the last few years the attention on PUFAs is increased because of their documented beneficial effects in preventing the occurrence of post-operative AF. The first demonstration of the beneficial effect of PUFA derives from the observation that consumption of fish or fish oil reduces the incidence of fatal ventricular arrhythmias, manifested as coronary death or sudden death. It is biologically plausible that this observed relationship is due to effects of longchain n-3 fatty acids in fatty fish [10] . Anti-arrhythmic action of PUFAs can be attributed to their inhibiting capacity of some ion channels and in particular sodium current, calcium current and potassium currents [11] . These effects cause an increased electrical stability that may result in a protection against AF [12] . In cultured rat atrial myocytes, n-3 fatty acids reduce induced asynchronous contractile activity [13] , suggesting that n-3 fatty acids from fish may have anti-arrhythmic effects on atrial muscle. Another study has demonstrated that oral n-3 PUFAs supplementation, in an animal model of atrial remodelling and AF, reduced AF inducibility and maintenance by activating matrix metalloproteinase-9 mRNA expression and attenuating collagen turnover [14] . However, pathophysiological mechanisms of postoperative AF were the focus of many studies and still remain partly unknown. Scientists are increasingly supporting the hypothesis of an important role of surgery-related inflammatory cascade as the leading cause of post-operative AF. Many studies evaluated CRP levels as prototypic marker of inflammation. Bruins et al. found that on the second post-operative day CRP levels peak as the incidence of AF [15] . Another study showed that CRP is not only associated with the presence of AF but it is also a risk factor for this specific arrhythmia [16] . A recent study found that dietary n-3 PUFA supplementation attenuates the inducibility and maintenance of AF in a canine sterile pericarditis model by reducing the production of proinflammatory cytokines such as CRP, IL-6, TNF-α [9] . There are several clinical studies reporting that PUFAs have beneficial effects in inflammatory disease [17] [18] . The anti-inflammatory effects of PUFA are due to various mechanisms: decreased proportions of arachidonic acid and eicosanoids in inflammatory cells [19] , decrease in chemotaxis of human neutrophils and monocytes [19] , reduced expression of adhesion molecules on monocytes, macrophages and endothelial cells surface [20] , reduced synthesis of inflammatory cytokines [9] . Consequently we can hypothesize that an anti-inflammatory action of PUFAs could play an important role in the prevention of AF after CABG.
In this trial we have demonstrated that PUFA administration significantly reduces the overall incidence of postoperative AF in patients undergoing CABG (11.4% absolute risk reduction, 49.8% relative risk reduction). In particular a statistically significant reduction of AF post-operative incidence was observed only in patients undergoing "onpump" CABG (19.8% absolute risk reduction, 62.7% relative risk reduction). This finding may further support the hypothesis of an anti-inflammatory PUFA action considering that "on-pump" CABG induces a systemic inflammatory response by triggering the production and release of inflammatory mediators. Several studies documented the efficacy of PUFA administration in preventing AF after coronary artery bypass graft surgery. Calò et al. showed that the use of PUFAs during hospitalization in patients undergoing CABG significantly reduced the incidence of postoperative AF and was associated with a shorter hospital stay, reporting the first direct evidence of an atrial anti-arrhythmic effect of PUFAs [6] . Other authors recently showed that pre-operative PUFA therapy was associated with a decreased incidence of early, but not late, AF after cardiac surgery [7] . A recent study did not confirm these previous findings, supporting the hypothesis that omega 3-PUFAs do not reduce the risk of AF after coronary artery bypass graft surgery; however, these results could be hampered by limited study population [21] . Our study is in agreement with previous studies reporting a beneficial effect of PUFA therapy in reducing the incidence of post-operative AF; furthermore, we demonstrated the PUFA beneficial effect is strictly dependent on specific surgical technique with benefit evident in patients undergoing "on-pump" CABG.
Conclusion
Pre-operative PUFA therapy in patients undergoing "off-pump" CABG has no substantial benefits. N-3 polyunsaturated fatty acids administration, despite not being able to reduce hospital stay, significantly reduces the incidence of post-operative atrial fibrillation in patients undergoing coronary artery bypass graft with "on-pump" technique. 
